News & Publications


Learn more about Prous Institute and our progress in drug discovery, technology, industry partnerships, collaborations and scientific articles.

Prous Institute to present at the Chem-Bio Informatics Society (CBI) Annual Meeting (Tokyo, Japan October 27-29, 2015)

2015 Oct 26 |

Prous Institute has been invited to speak at the Chem-Bio Informatics Society (CBI) Annual Meeting "Open Innovation in drug discovery: emerging fields accelerated by in silico technologies " which takes place in Tokyo, Oct. 27-29, 2015.  

During the CBI session "Computational Toxicology Focused" Oct. 27 (Tue) 16:00-17:30, Josep Prous, Jr., Ph.D., Vice President Research and Development at Prous Institute for Biomedical Research, will present “In-silico off-target pharmacology profiling for minimizing safety-related attrition rates”.  

In his presentation, Dr Prous will describe how when considering opportunities for new small molecule therapeutic interventions, it is essential not only to identify beneficial mechanisms of action but also those which can be linked to undesired off-target activities leading to potential safety issues.  

Bearing in mind that the cost of experimentally screening thousands of drug candidates can be tremendous, using predictive technologies can be of special benefit to minimize the need for experimental validation and focus on molecules which are likely to be devoid of potential safety issues.  

Taking this scenario into consideration, Prous Institute for Biomedical Research has developed an innovative in silico solution, Symmetry, to accelerate drug discovery and minimize potential liabilities.    

The platform helps to de-risk and prioritize projects and assays and speed up drug discovery and development, reducing time, costs and attrition rates. Symmetry applies advanced machine learning techniques to a variety of structural features and physicochemical properties of small molecules to provide quality predictions of biological effects.  

Symmetry’s Global Mechanism of Action model predicts on- and off-target activities of small molecules and is based on a large training set of over 1 million compounds and over 1.5 million Structure-Activity Relationships (SAR).  

For further information or to schedule a meeting during the conference, please contact  

About the Chem-Bio Informatics Society 

The Chem-BioInformatics (CBI) Society is a Japanese non-profit organization that aims to provide a platform for promoting cutting-edge interdisciplinary areas related to chemistry, biology, and informatics. The CBI Society has interest in: molecular recognition and molecular modeling, in silico drug discovery, bioinformatics and its applications in medicine, information and computing approaches for drug design and ADMET studies, and emerging new technologies.      

About Prous Institute for Biomedical Research  

Prous Institute for Biomedical Research is a privately-held research organization. It was founded as a spin-off of Prous Science, the leading scientific information provider (producer of Drugs of the Future, Drug Data Report and the Integrity drug discovery and development portal, amongst others) acquired by Thomson Reuters in 2007. Prous Institute built on over 50 years of experience creating and managing biomedical knowledge to develop Symmetry, an innovative predictive analytics platform that enables the generation of new research hypotheses and predicts the therapeutic and safety profile of small molecules.